TNFRSF8 and HIV infectious disease: Brentuximab vedotin (BV), an antibody–drug conjugate (ADC) composed of the anti-CD30 monoclonal antibody cAC10, has been reported to have a dual effect on HIV-related PEL, effectively controlling lymphoma and HIV infection [84].